Published in Parkinsonism Relat Disord on September 09, 2005
Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest (2008) 2.91
CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J Neuroimmune Pharmacol (2012) 1.78
Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One (2008) 1.65
Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol (2008) 1.45
Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One (2010) 1.29
Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol (2009) 1.27
Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.22
Proteomic studies of nitrated alpha-synuclein microglia regulation by CD4+CD25+ T cells. J Proteome Res (2009) 1.13
Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease. Mediators Inflamm (2013) 1.12
A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice. Neurotherapeutics (2012) 1.11
Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol (2012) 1.10
Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro (2013) 1.05
The role of innate and adaptive immunity in Parkinson's disease. J Parkinsons Dis (2013) 1.03
Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses. BMC Med (2015) 0.97
Mesenchymal stem cells in a transgenic mouse model of multiple system atrophy: immunomodulation and neuroprotection. PLoS One (2011) 0.96
Parkinson's disease and systemic inflammation. Parkinsons Dis (2011) 0.96
Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson's disease. Parkinsons Dis (2010) 0.95
Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease. J Parkinsons Dis (2015) 0.93
Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies. Biomed Res Int (2015) 0.92
Microphthalmia, parkinsonism, and enhanced nociception in Pitx3 ( 416insG ) mice. Mamm Genome (2009) 0.89
Dopaminergic Receptors on CD4+ T Naive and Memory Lymphocytes Correlate with Motor Impairment in Patients with Parkinson's Disease. Sci Rep (2016) 0.87
Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders. Transl Neurodegener (2014) 0.86
Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease. J Mol Cell Biol (2014) 0.85
Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy? Parkinsons Dis (2011) 0.85
Converging mediators from immune and trophic pathways to identify Parkinson disease dementia. Neurol Neuroimmunol Neuroinflamm (2016) 0.84
Pathways towards an effective immunotherapy for Parkinson's disease. Expert Rev Neurother (2011) 0.84
Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study. Gut Pathog (2012) 0.84
Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance. Curr Neuropharmacol (2012) 0.83
Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance? Hum Vaccin Immunother (2014) 0.82
Nelfinavir monotherapy increases naïve T-cell numbers in HIV-negative healthy young adults. Front Biosci (2008) 0.81
A critical role for alpha-synuclein in development and function of T lymphocytes. Immunobiology (2015) 0.81
Relevance of chronic stress and the two faces of microglia in Parkinson's disease. Front Cell Neurosci (2015) 0.81
Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse model of Parkinson's disease. Glia (2015) 0.81
T-Lymphocyte Deficiency Exacerbates Behavioral Deficits in the 6-OHDA Unilateral Lesion Rat Model for Parkinson's Disease. J Neurol Neurophysiol (2014) 0.81
Peripheral leukocyte apoptosis in patients with Parkinsonism: correlation with clinical characteristics and neuroimaging findings. Biomed Res Int (2014) 0.80
Blood profile holds clues to role of infection in a premonitory state for idiopathic parkinsonism and of gastrointestinal infection in established disease. Gut Pathog (2009) 0.80
Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease. Int J Neuropsychopharmacol (2014) 0.79
Damage of neuroblastoma cell SH-SY5Y mediated by MPP+ inhibits proliferation of T-cell leukemia Jurkat by co-culture system. Int J Mol Sci (2014) 0.79
PACAP deficiency sensitizes nigrostriatal dopaminergic neurons to paraquat-induced damage and modulates central and peripheral inflammatory activation in mice. Neuroscience (2013) 0.79
Nanowire array chips for molecular typing of rare trafficking leukocytes with application to neurodegenerative pathology. Nanoscale (2014) 0.78
Infiltrating T lymphocytes reduce myeloid phagocytosis activity in synucleinopathy model. J Neuroinflammation (2016) 0.77
Current Challenges Towards the Development of a Blood Test for Parkinson's Disease. Diagnostics (Basel) (2014) 0.77
Comparison of neutrophil-lymphocyte ratio (NLR) in Parkinson's disease subtypes. Neurol Sci (2016) 0.76
Herpes zoster correlates with increased risk of Parkinson's disease in older people: A population-based cohort study in Taiwan. Medicine (Baltimore) (2017) 0.75
Mitochondrial and cytosolic roles of PINK1 shape induced regulatory T-cell development and function. Eur J Immunol (2013) 0.75
α-Synuclein vaccination modulates regulatory T cell activation and microglia in the absence of brain pathology. J Neuroinflammation (2016) 0.75
Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease. J Neural Transm (Vienna) (2015) 0.75
Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial. NPJ Parkinsons Dis (2017) 0.75
The correlation of lymphocyte subsets, natural killer cell, and Parkinson's disease: a meta-analysis. Neurol Sci (2017) 0.75
Mitochondria-Derived Damage-Associated Molecular Patterns in Neurodegeneration. Front Immunol (2017) 0.75
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron (2011) 20.15
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
VPS35 mutations in Parkinson disease. Am J Hum Genet (2011) 4.16
DCTN1 mutations in Perry syndrome. Nat Genet (2009) 3.87
Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet (2008) 3.66
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol (2011) 3.36
Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol (2011) 3.34
Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet (2005) 3.29
Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain (2012) 3.08
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology (2010) 2.84
Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet (2011) 2.76
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet (2008) 2.48
Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain (2012) 2.43
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain (2005) 2.40
Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics (2005) 2.31
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol (2012) 2.20
Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol (2007) 2.19
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Lrrk2 and Lewy body disease. Ann Neurol (2006) 2.00
Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet (2011) 2.00
Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med (2012) 1.99
Sporadic SCA8 mutation resembling corticobasal degeneration. Parkinsonism Relat Disord (2005) 1.97
TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol (2014) 1.90
Rapidly progressive familial parkinsonism with central hypoventilation, depression and weight loss (Perry syndrome)--a literature review. Parkinsonism Relat Disord (2007) 1.88
Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain (2005) 1.85
TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener (2013) 1.83
Mutations in CIZ1 cause adult onset primary cervical dystonia. Ann Neurol (2012) 1.82
Investigating the role of FUS exonic variants in essential tremor. Parkinsonism Relat Disord (2013) 1.79
Role of Gα(olf) in familial and sporadic adult-onset primary dystonia. Hum Mol Genet (2013) 1.79
Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol (2008) 1.72
C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology (2013) 1.70
Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet (2011) 1.60
SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia. Neurogenetics (2013) 1.58
Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet (2006) 1.56
Heredofamilial brain calcinosis syndrome. Mayo Clin Proc (2005) 1.54
DNAJC13 mutations in Parkinson disease. Hum Mol Genet (2013) 1.54
Mortality in Parkinson's disease. Mov Disord (2010) 1.51
De novo truncating FUS gene mutation as a cause of sporadic amyotrophic lateral sclerosis. Hum Mutat (2010) 1.49
Body mass index is reduced early in Parkinson's disease. Parkinsonism Relat Disord (2005) 1.47
Hereditary diffuse leukoencephalopathy with spheroids: clinical, pathologic and genetic studies of a new kindred. Acta Neuropathol (2006) 1.47
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet (2012) 1.46
Dopamine agonist therapy for Parkinson disease and pathological gambling. Parkinsonism Relat Disord (2006) 1.45
Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun (2006) 1.45
Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J Neuropathol Exp Neurol (2008) 1.45
Reported mutations in GIGYF2 are not a common cause of Parkinson's disease. Mov Disord (2009) 1.43
Human herpesvirus 6 encephalitis associated with hypersensitivity syndrome. Ann Neurol (2002) 1.42
Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Ann Neurol (2011) 1.40
Severe vascular disturbance in a case of familial brain calcinosis. Acta Neuropathol (2005) 1.38
LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics (2010) 1.37
Atypical progressive supranuclear palsy with corticospinal tract degeneration. J Neuropathol Exp Neurol (2006) 1.34
Genetic variation of Omi/HtrA2 and Parkinson's disease. Parkinsonism Relat Disord (2008) 1.34
Neurodegeneration involving putative respiratory neurons in Perry syndrome. Acta Neuropathol (2007) 1.33
Unsaturated fatty acids suppress the expression of the ATP-binding cassette transporter G1 (ABCG1) and ABCA1 genes via an LXR/RXR responsive element. Atherosclerosis (2006) 1.33
Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neurodegener Dis (2010) 1.31
Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. Neurobiol Aging (2012) 1.30
The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet (2003) 1.30
Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat Disord (2008) 1.29
Genomewide association, Parkinson disease, and PARK10. Am J Hum Genet (2006) 1.28
Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord (2004) 1.27
CSF1R mutations link POLD and HDLS as a single disease entity. Neurology (2013) 1.27
Defining the Parkinson's disease phenotype: initial symptoms and baseline characteristics in a clinical cohort. Parkinsonism Relat Disord (2005) 1.25
Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms. Am J Hum Genet (2007) 1.24
MR imaging of brainstem atrophy in progressive supranuclear palsy. J Neurol (2007) 1.21
Familial idiopathic basal ganglia calcification: a challenging clinical-pathological correlation. J Neurol (2009) 1.20
Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain (2011) 1.18